LH for use in maintaining one or more pregnancies by inducing accessory corpus luteum formation.

(19)

(11)

EP 1 610 803 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	14.09.2011 Bulletin 2011/37

(45)	Mention of the grant of the patent:
	15.12.2010 Bulletin 2010/50

(21)	Application number: 04717460.2

(22)	Date of filing: 04.03.2004

(51)

International Patent Classification (IPC):

A61K 38/24^(2006.01)

A61P 15/06^(2006.01)

(86)	International application number:
	PCT/US2004/006789

(87)	International publication number:
	WO 2004/078061 (16.09.2004 Gazette 2004/38)

(54)

LH for use in maintaining one or more pregnancies by inducing accessory corpus luteum formation.

LH zur Verwendung der Erhaltung einer oder mehreren Schwangerschaften durch Induktion der Bildung des sekundären Gelbkörpers.

LH pour utilisation pour maintenir une ou plusieurs grossesses en induisant la formation du corps jaune secondaire.

(84)	Designated Contracting States:
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

(30)

Priority:

04.03.2003 US 452297 P
31.10.2003 US 516002 P

(43)	Date of publication of application:
	04.01.2006 Bulletin 2006/01

(73)	Proprietor: AspenBio Pharma, Inc.
	Castle Rock, CO 80104 (US)

(72)	Inventors:
	MCSWEENEY, Kevin Loveland, CO 80537 (US) COLGIN, Mark Castle Rock, CO 80109 (US) NEWMAN, Diane Castle Rock, CO 80109 (US) ROTH, Jay. W. Golden, CO 80401 (US) HURST, Roger Castle Rock, CO 80109 (US)

(74)	Representative: Walker, Ross Thomson
	Forrester & Boehmert Pettenkoferstrasse 20-22 80336 München 80336 München (DE)

(56)

References cited: :

WO-A-00/09113
GB-A- 1 274 492
US-A- 3 636 193
US-A- 5 610 138

GB-A- 1 161 836
US-A- 3 574 829
US-A- 3 947 569

MARTINEZ MF, KASTELIC JP, ADAMS GP, MAPLETOFT RJ: "The use of a progesteron-releasing device (CIDR-B) or melengestrol acetate with GnRH, LH, or estradiol benzoate for fixed-time AI in beef heifers" J ANIM SCI, vol. 80, 2002, pages 1746-1751, XP002466540
DE ARAUJO BERBER RC, MADUREIRA EH, BARUSELLI PS: "Comparison of two Ovsynch protocols (GnRH versus LH) for fixed timed insemination in buffalo (Bubalus bubalis)" THERIOGENOLOGY, vol. 57, no. 5, 15 March 2002 (2002-03-15), pages 1421-1430, XP002466541
GORDON U D ET AL: "A randomized prospective asessor-blind evaluation of luteinizing hormone dosage and in vitro fertilization outcome" FERTILITY AND STERILITY, ELSEVIER SCIENCE INC, NEW YORK, NY, US, vol. 75, no. 2, February 2001 (2001-02), pages 324-330, XP002199282 ISSN: 0015-0282
'Superovulation of Cattle, Medically Assisted Conception' AN AGENDA FOR RESEARCH, [Online] 1989, THE NATIONAL ACADEMY OF SCIENCES, pages 131 - 132, XP002903951 Retrieved from the Internet: <URL:http://nap.edu/openbook/0309041287/htm l/131.htm.>
'Genetic Management of Breeding Colonies' RODENTS. THE NATIONAL ACADEMY OF SCIENCES, [Online] 1996, pages 35 - 43, XP002903952 Retrieved from the Internet: <URL:http://www.nap.edu/openbook/0390409369 /html/35.html>

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).